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OBJECTIVES: Henoch-Scho¨nlein purpura nephritis and immunoglobulin A nephropathy are two diseases with
similar clinical presentations but very different prognoses. Transforming growth factor b1 and monocyte chemo-
attractant protein-1 have been associated with the development of tissue fibrosis. We examined the development
of tubulointerstitial fibrosis and its relationship with Transforming growth factor b1 and monocyte chemo-
attractant protein-1 expression in these patients.
METHODS: Renal tissue samples were collected by renal biopsy from 50 children with Henoch-Scho¨nlein
purpura nephritis and 50 children with immunoglobulin A nephropathy. Hematoxylin and eosin and Masson’s
trichrome-stained tissues were examined using light microscopy. Tubulointerstitial fibrosis was graded using the
method described by Bohle et al. (1). The immunohistochemical detection of Transforming growth factor b1 and
monocyte chemoattractant protein-1 expression was correlated with the tubulointerstitial fibrosis grade.
Clinical Trial registration number: ZJCH-2012-0105.
RESULTS: Transforming growth factor b1 and monocyte chemoattractant protein-1 expression in the renal
tissues was significantly greater in the patients with immunoglobulin A nephropathy than in the patients with
Henoch-Scho¨nlein purpura nephritis (both po0.001). The immunoglobulin A nephropathy patients had a
higher tubulointerstitial fibrosis grade than the Henoch-Scho¨nlein purpura nephritis patients (po0.001). The
tubulointerstitial fibrosis grade was in accordance with the Transforming growth factor b1 and monocyte
chemoattractant protein-1 expression levels in both diseases (both po0.001).
CONCLUSION: Transforming growth factor b1 and monocyte chemoattractant protein-1 expression was
associated with the development of immunoglobulin A nephropathy and Henoch-Scho¨nlein purpura nephritis.
Further studies are needed to better evaluate this association.
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’ INTRODUCTION
Henoch-Schönlein purpura (HSP) is one of the most com-
mon childhood vasculitides (2). Approximately 30 to 50%
of children with HSP have nephritis (HSPN), which most
commonly presents with hematuria and/or proteinuria. The
microscopic findings of this disease include mesangial cell
proliferation, crescent formation in epithelial cells, and mesangial
IgA deposition (3). Most HSPN patients have a good prog-
nosis (4). Although HSPN has been related to infection and
allergies (5), the exact etiology and pathogenesis of this
disease are unknown.
Immunoglobulin A nephropathy (IgAN) is the most com-
mon primary glomerular disease worldwide. IgAN is char-
acterized by IgA or IgA immune complex deposition in the
glomerular mesangial region with mesangial cell prolifera-
tion (6). The main clinical findings are isolated hematuria or
proteinuria. A total of 15 to 20% of IgAN patients develop
chronic renal failure within 10 years of their diagnosis. IgAN
is one of the leading causes of end-stage renal disease in
China (7). Although HSPN and IgAN share some manifesta-
tions (8), their prognoses are very different.
Tubulointerstitial damage is a key factor in determining
the prognosis of IgAN patients (9,10). Tubulointerstitial damageDOI: 10.6061/clinics/2017(02)05
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in the setting of IgAN includes tubular epithelial cell degen-
eration, necrosis, or atrophy, interstitial inflammatory cell
infiltration and fibrosis (11), tubular atrophy, interstitial lym-
phatic and mononuclear cell infiltration and fibrosis. The
degree of tubulointerstitial fibrosis has been associated with
the severity of renal impairment and the patient prognosis in
both disease states (12-14). However, whether tubulointersti-
tial fibrosis is more severe in IgAN patients than in HSPN
patients is unknown.
The causes of tubulointerstitial fibrosis are not entirely
clear; however the association between transforming growth
factor b1 (TGF-b1) and monocyte chemoattractant protein-1
(MCP-1) expression and the development of tissue fibrosis is
well documented (15). TGF-b1 is a cytokine with powerful
stimulatory effects on collagen production in vivo. Hypoxia,
high serum glucose and high plasma protein levels stimulate
TGF-b1 expression in human proximal tubular epithelial cells
(16) and have been linked to the development of tubuloin-
terstitial fibrosis (8,17). MCP-1 is a chemotactic factor that
activates monocytes and macrophages and mediates the
interstitial inflammation that precedes fibrosis. However, no
reports have compared TGF-b1 or MCP-1 expression in the
renal tissues from children with HSPN and IgAN.
We examined renal tissues from children with HSPN and
IgAN and determined the association between TGF-b1 and
MCP-1 expression and tubulointerstitial fibrosis.
’ METHODS
Study Subjects
Fifty children with HSPN and 50 children with IgAN were
admitted to the Department of Nephrology, The Children’s
Hospital, Zhejiang University School of Medicine Hospital,
between May 2012 and April 2014. The patients had similar
clinical presentations with proteinuria and hematuria. The
patients underwent rheumatic and anti-neutrophil cytoplas-
mic antibody testing to exclude vasculitis and autoimmune
diseases. The HSPN diagnosis was based on the criteria recom-
mended by the Nephrology Group of the Chinese Medical
Society (18) in November 2000. A total of 32 males and
18 females with HSPN were enrolled with a mean age of
8.3±2.5 years (range: 4–13 years). The IgAN diagnosis was
based on the primary glomerular nephropathy classification
criteria recommended by the World Health Organization
(WHO) in 1995 (18). A total of 34 males and 16 females with
IgAN were enrolled with a mean age of 8.8±2.1 years (range:
4–15 years). The two diagnostic groups had similar age and
gender distributions. Light microscopic, immunofluorescence
and electron microscopic examinations of the renal tissues
were performed to confirm all diagnoses (data not shown).
Patients with kidney dysfunction secondary to other diseases
were excluded from this study. Informed consent was obtained
from the parents of all patients. The study protocol was
approved by the local institutional ethnics committee and was
in accordance with the tenets of the Declaration of Helsinki.
Written informed consent was obtained from all study parti-
cipants after the nature of the study was explained. Clinical
Trial registration number: ZJCH-2012-0105.
Renal Tissue Collection
All patients underwent ultrasound guided renal biopsy.
Two renal cores were collected from each patient. Each speci-
men was 1 cm to 2 cm in length. The tissues were fixed with
neutral formalin solution for 24 hr and embedded in paraffin.
One specimen underwent hematoxylin and eosin (H&E) and
Masson’s trichrome staining for the pathological diagnosis,
and the second specimen was used for TGF-b1 and MCP-1
immunohistochemical testing.
Glomerular Pathological Classification
The HSPN glomerular findings were graded according to
the International Study of Kidney Disease in Children (ISKDC)
classifications as follows: grade I, minimal glomerular abnor-
malities; grade II, mesangial proliferation without crescents;
grade III, focal segmental (IIIa) or diffuse (IIIb) mesangial pro-
liferation with less than 50% crescents; grade IV, mesangial
proliferation with 50 to 75% crescents; grade V, mesangial
proliferation with greater than 75% crescents; and grade VI,
membranoproliferative-like lesions.
IgAN was classified into five grades as follows: grade I,
mostly normal glomeruli under the light microscope and mild
mesangial proliferation without cellular proliferation; grade II,
mild mesangial widening and mesangial cell proliferation
with no more than three mesangial cells in each mesangial
area; grade III, focal segmental glomerulonephritis with less
than 50% focal or segmental glomerular, mesangial cell pro-
liferation, and minor lesions with occasional adhesions and
small crescents in the remaining glomeruli; grade IV, diffuse
mesangial proliferative glomerulonephritis with significant
glomerular diffuse mesangial proliferation and sclerosis and
varying degrees of cell proliferation, common abandoned glo-
meruli, and adhesions and crescents in less than 50% of the
glomeruli; and grade V, diffuse sclerosing glomerulonephritis
in more than 80% of the glomeruli and crescents in more than
50% of the glomeruli (19).
Grading of Tubulointerstitial Fibrosis
An experienced pathologist reviewed the H&E andMasson’s
trichrome-stained tissues (Supplementary Figure 1A–D) to
grade the level of tubulointerstitial fibrosis. Tubulointerstitial
fibrosis was graded using themethod described by Bohle et al. (1).
Grade + was defined as normal tubulointerstitial tissue with
mild tubular degeneration, grade++ as tubulointerstitial fibrosis
with less than 20% tubular atrophy and scattered inflamma-
tory cell infiltrates, grade +++ as tubulointerstitial fibrosis
with 30 to 40% tubular atrophy and scattered and/or diffuse
inflammatory cell infiltrates, and grade++++ as tubuloin-
terstitial fibrosis with more than 50% tubular atrophy and
scattered and/or diffuse inflammatory cell infiltrates (1).
Renal TGF-b1 and MCP-1 Expression
Immunohistochemical (IHC) staining of paraffin sections
was performed using the EnVisionTM+ Kit (Dako, Denmark)
according to the manufacturer’s instructions. Briefly, 1) the
paraffin sections were dewaxed in xylene and then rinsed in
graduated absolute ethanol solutions (95%, 80%, and 70%
ethanol) and water. 2) The sections were washed with distilled
water. 3) Antigen retrieval was performed using high temper-
ature and high pressure for 100 sec in a 0.01 M (pH 6.0) citrate
buffer solution. 4) The sections were washed with distilled
water and then with PBS 3 times for 5 min per wash.
5) Endogenous peroxidase was blocked using 3% H2O2 for
10 min. 6) The tissue sections were washed with PBS 3 times
for 5 min per wash. 7) An appropriately diluted primary
antibody was added to the sections and incubated at 37oC for
1 hr (TGF-b1 (Santa cruz, California, American) at a 1:75 dilution
and MCP-1 (Abcam, Cambridge, England) at a 1:100 dilution)
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Supplementary Figure 1 - Grading of fibrosis and protein expression in renal tissues. Panels A, B, C and D show tubulointerstitial fibrosis
grades+,++,+++ and++++, respectively. Panels A, C, and D were stained with hematoxylin and eosin, and Panel B was stained
with Masson’s trichrome stain. Panels E, F, G and H show the immunohistochemical expression of TGF-b1 in the renal tubular cytoplasm
of patients with IgAN. The staining intensity was -,+,++ and+++, respectively. Panels I, J, K and L show the immunohistochemical
expression of MCP-1 in the renal tubular cytoplasm of patients with HSPN. The staining intensity was -,+,++ and+++, respectively.
The magnification for all slides was 200 .
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Supplementary Figure 1 - Continued
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and then at 4oC overnight. The substitution of PBS for the
primary antibody was used as a negative control. 8) The slides
were washed in PBS 3 times for 5 min per wash. 9) A sec-
ondary antibody (i.e., goat anti-rabbit IgG antibody-HRP
multimers) was added to the sections and incubated at 37oC
for 40 min. 10) The slides were washed in PBS 3 times for
5 min per wash. 11) Color development was performed using
a DAB chromogenic agent for 1–3 min; the staining intensity
was controlled under microscopic observation. The reaction
was terminated by washing the slide with tap water. 12) The
slides were stained using the Harris hematoxylin nuclear stain
for 1 min and mounted with neutral resin.
TGF-b1 expression was observed in the cytoplasm of the
renal tubular epithelial cells, some interstitial inflammatory
cells, glomerular endothelial cells, mesangial cells and epithelial
cells. MCP-1 was expressed in cytoplasm of the glomerular
endothelial cells, mesangial cells, epithelial cells, tubular
epithelial cells, and endothelial cells of small interstitial blood
vessels. The appearance of yellow or brown particles in the
cytoplasm after IHC staining was considered positive expres-
sion. The expression levels were compared to the negative
controls. Expression was graded according to the scope and
intensity of the staining as follows (20): negative ( ), no positive
staining (Supplementary Figure 1E, 1I); weak positive (+),
occasional positive staining with pale yellow in less than 25% of
the cells (Supplementary Figure 1F, 1J); positive (++), dark
yellow staining in 26% to 50% of the cells (Supplementary
Figure 1G, 1L); and strong positive (+++), brown staining in
more than 50% of the cells (Supplementary Figure 1H, 1K).
Statistical Analysis
Normally distributed data were expressed as the mean ±
standard deviation. Non-normally distributed data were
expressed as the median. Fisher’s exact test, the Chi-square
test or a T test were used for comparisons between groups. The
Mann-Whitney rank sum test was used to compare the TGF-b1
and MCP-1 expression levels between the two diagnostic
groups. The Spearman rank correlation analysis was used to
evaluate correlations between the TGF-b andMCP-1 expression
levels and the grade of tubulointerstitial fibrosis. The SPSS 11.5
software was used for the statistical analysis. A p value less
than 0.05 was considered statistically significant.
’ RESULTS
Evaluation of Demographic Findings in Patients
with HSPN and IgAN
The clinical features and intensity of proteinuria in
50 children with HSPN and 50 children with IgAN are sum-
marized in Tables 1 and 2. No differences were observed in
the clinical findings of the two groups of patients (p=0.18;
Table 1), but a significant difference was detected in the
proteinuria intensity (p=0.026; Table 2).
Evaluation of Tubulointerstitial Fibrosis
The IgAN patients had significantly more severe tubu-
lointerstitial fibrosis than the HSPN patients (Ppo0.001;
Table 3) (Supplementary Figure 1A–D).
Correlation between the Tubulointerstitial Fibrosis
Grade and the Glomerular Findings in Children with
HSPN and IgAN
The tubulointerstitial fibrosis grade was moderately cor-
related with the glomerular findings in both disease groups
(HSPN, Spearman correlation coefficient=0.55, po0.001;
IgAN, Spearman correlation coefficient=0.63, po0.001)
(Table 4).
Table 2 - Intensity of proteinuria in patients with HSPN and
IgAN.
24 h proteinuria HSPN IgAN Z p
n % n %
o25 mg/kg 19 41.3% 8 16.7% 2.23 0.026
25-50 mg/kg 17 36.9% 25 52.1%
50 mg/kg 10 21.7% 15 31.2%
Table 1 - Clinical findings in patients with HSPN and IgAN.
Clinical finding HSPN IgAN w2 p
n % n %
Proteinuria 46 92% 48 96% 4.89 0.18
Hematuria and proteinuria 25 50% 20 40%
Acute nephritis 5 10% 10 20%
Nephrotic syndrome 10 20% 5 10%
Rapidly progressive glomerulonephritis 0 0
Table 3 - Grading of tubulointerstitial fibrosis in patients with
HSPN and IgAN.
Fibrosis grade HSPN IgAN
I 38 5
II 9 17
III 2 20
IV 1 8
Total 50 50
Z=6.74, po0.001, by Mann–Whitney–Wilcoxon test.
Table 4 - Correlation between the tubulointerstitial fibrosis
grade and the glomerular pathological findings in patients with
HSPN and IgAN.
Disease grade Grade of fibrosis
in HSPNa
Grade of fibrosis
in IgANb
I–II III IV–V I–II III IV–V
I 26 12 0 4 1 0
II 2 6 1 13 3 1
III 0 0 2 3 13 4
IV 0 0 1 1 8 5
V 0 0 0 0 0 0
aw2=21.44, Ppo0.001 for children with HSPN, and bw2=17.83, po0.001 for
children with IgAN.
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TGF-b1 and MCP-1 Expression in HSPN and
IgAN Patients
TGF-b1 and MCP-1 expression was significantly greater in
the IgAN patients than in the HSPN patients (po0.001 for
both) (Figure 1).
Correlation between the Tubulointerstitial Fibrosis
Grade and TGF-b1 and MCP-1 Expression
The tubulointerstitial fibrosis grade was moderately cor-
related with TGF-b1 and MCP-1 expression in both disease
groups (HSPN: Spearman correlation coefficient for TGF-b1=
0.56, po0.001; Spearman correlation coefficient for MCP-1=
0.63, po0.001; IgAN: Spearman correlation coefficient for
TGF-b1=0.72, po0.001; Spearman correlation coefficient for
MCP-1=0.62, po0.001) (Tables 5–8).
’ DISCUSSION
Increased TGF-b1 and MCP-1 expression has been reported
in many fibrotic diseases (21). TGF-b1 is a cytokine that is
expressed in the kidney in association with the development
of tubulointerstitial fibrosis (22). MCP-1 plays a role in the
chemotaxis and activation of monocytes and macrophages.
Tubulointerstitial injury is related to monocyte and macro-
phage infiltration, which stimulates the ingrowth of activated
neutrophils, mononuclear cells, and subsequent T cell infiltra-
tion and in turn stimulates the growth of fibroblasts and
keratinocytes (23). MCP-1 also stimulates the expression of
IL-6, cell adhesion molecules, and other inflammatory factors
that contribute to renal tubular fibrosis (24).
TGF-b1 has been hypothesized to participate in the initia-
tion and progression of early immune renal tubular injury
and the formation of tubulointerstitial fibrosis (25). Yamumoto
et al. (17). examined renal tissues from patients with different
types of renal disease. Patients with thin basement membrane
nephropathy or minimal change nephropathy had TGF-b1
Table 5 - Correlation between the tubulointerstitial fibrosis
grade and MCP-1 expression in children with HSPN.
Fibrosis
grade
n MCP-1 expression
- + ++ +++
I 38 12 23 3 0
II 9 0 3 6 0
III 2 0 0 1 1
IV 1 0 0 0 1
Total 50 12 26 10 2
Spearman correlation coefficient for MCP-1=0.63, po0.001.
Table 6 - Correlation between the tubulointerstitial fibrosis
grade and TGF-b1 expression in HSPN.
Fibrosis
grade
n TGF-b1 expression
- + ++ +++
I 38 15 21 2 0
II 9 0 6 3 0
III 2 0 0 1 1
IV 1 0 0 0 1
Total 50 15 27 6 2
Spearman correlation coefficient for TGF-b1=0.56, po0.001.
Table 7 - Correlation between the tubulointerstitial fibrosis
grade and MCP-1 expression in IgAN.
Fibrosis
grade
n MCP-1 expression
- + ++ +++
I 5 4 1 0 0
II 17 2 7 4 4
III 20 0 2 14 4
IV 8 0 0 2 6
Total 50 6 10 20 14
Spearman correlation coefficient for MCP-1=0.62, po0.001.
Table 8 - Correlation between the tubulointerstitial fibrosis
grade and TGF-b1 expression in IgAN.
Fibrosis
grade
n TGF-b1 expression
- + ++ +++
I 5 3 2 0 0
II 17 2 11 4 0
III 20 0 8 12 0
IV 8 0 0 3 5
Total 50 5 21 19 5
Spearman correlation coefficient for TGF-b1=0.72, po0.001.
Figure 1 - Immunohistochemical staining scores for TGF-b1 (A)
and MCP-1 (B) in patients with HSPN and IgAN. The stain-
ing scores were compared between the two groups of patients
with the Mann–Whitney–Wilcoxon test. Z=3.6013, p=0.0003 for
TGF-b1 and Z=3.94, po0.001 for MCP-1.
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mRNA expression levels that were similar to the normal con-
trol patients. Conversely, patients with IgAN, HSPN, lupus
nephritis or crescent nephritis and glomerular or tubulointer-
stitial disease had significantly greater renal TGF-b1 mRNA
expression levels than the normal control patients, which was
consistent with our findings. We found that the IHC expres-
sion of TGF-b1 in the renal tubular epithelial cells was posi-
tively correlated with the tubulointerstitial fibrosis grade in
children with IgAN. Together, these findings suggest that
renal TGF-b1 expression may be related to tubulointerstitial
disease and impaired renal tubular functions in IgAN patients.
A study of 25 adult IgAN cases by Celie et al. (26)
demonstrated an association between MCP-1 expression and
the degree of glomerular and tubulointerstitial injury. MCP-1
expression in the tubulointerstitial tissues was positively
correlated with the amount of proteinuria. MCP-1 expression
in the glomerular and tubulointerstitial tissues was sug-
gested to be a possible indicator of renal disease severity in
IgAN patients. We found a positive correlation between
MCP-1 expression and the grade of tubulointerstitial fibrosis.
Together, these findings suggest that MCP-1 expression is
related to the tubulointerstitial fibrosis and impaired tubular
function found in IgAN patients.
Patients with HSPN typically present with acute episodes
of glomerular inflammation consisting of mesangial pro-
liferation, fibrin deposits and epithelial crescents that heal
spontaneously or lead to chronic lesions. Sick children with
HSPN suffer from humoral immune abnormalities, T cell
subset dysfunction, and abnormal cytokine production.
These findings may lead to TGF-b1 expression, which can
mediate fibrosis formation. In contrast, patients with IgAN
typically have an IgA-based granular sediment deposited in
the glomerulus mesangial region. These patients develop
slowly progressive mesangial lesions from the continuous
low-grade deposition of macromolecular IgA1. Abnormal
IgA1 glycosylation in these patients is associated with renal
deposition and complement system activation. The children
with HSPN examined in this study had low renal TGF-b1
and MCP-1 expression, whereas the IgAN patients com-
monly had high expression levels of these cytokines. The
mechanism of inflammation initiation appears to be more
active in patients with IgAN, which may explain why these
patients have more fibrosis and higher TGF-b1 and MCP-1
expression levels than the HSPN patients.
Increased renal TGF-b1 and MCP-1 expression was asso-
ciated with increased tubulointerstitial fibrosis in both disease
states. Tubulointerstitial fibrosis was observed in both diag-
nostic groups but was more common in the IgAN group.
We found a similar positive moderate correlation between the
tubulointerstitial fibrosis grade and the intensity of protei-
nuria and TGF-b1 and MCP-1 expression in both diseases.
The relative frequency of cytokine expression suggests that
TGF-b1 and MCP-1 are likely linked to tubulointerstitial
fibrosis formation in both disease groups. Several studies have
shown that higher proteinuria levels are related to the
progression of renal diseases in patients with different types
of glomerulopathy (27), which is consistent with the results of
our study (Table 2). One possible mechanism is that the
increase in protein reabsorption by the tubule cells leads to
changes in these cells, which start to produce cytokines and
chemoattractant factors for lymphocytes and macrophages;
then, these cells migrate to the interstitial area to induce
inflammation and fibrosis (28-30). Further work is needed
to better understand the development of inflammation and
TGF-b1 and MCP-1 expression in these patients and the
progression to tubulointerstitial fibrosis.
In summary, we observed tubulointerstitial fibrosis in the
renal tissues of children with HSPN and IgAN. Greater
tubulointerstitial fibrosis was observed in the IgAN patients
compared to the HSPN patients. Increased amounts of tubu-
lointerstitial fibrosis were associated with increased TGF-b1
and MCP-1 expression. These findings suggest that TGF-b1
and MCP-1 may be involved in the development of tubu-
lointerstitial fibrosis in both these disease states, possibly
through different inflammatory mechanisms.
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